Navigation Links
Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
Date:11/13/2013

SALT LAKE CITY, Nov. 13, 2013 /PRNewswire/ -- Jade Therapeutics, Inc. announced today the election of veteran life science entrepreneur and venture capitalist Dinesh Patel, Ph.D., to the Company's Board of Directors, replacing SCI Institute Associate Director Dr. Greg Jones.

(Logo: http://photos.prnewswire.com/prnh/20131113/PH15704LOGO

Dr. Patel co-founded the venture capital firm vSpring Capital (now Signal Peak Ventures) in 2000 and is currently Partner Emeritus. From 1985-1999, he served as Co-Founder, Chairman, and President & CEO of TheraTech, Inc., a biotechnology company that he took public and eventually sold to Watson Pharmaceuticals for $350 million. He was also Founder, Chairman, President & CEO of Ashni Naturaceuticals, and he co-founded and was Chairman of the biotechnology company Salus Therapeutics. In addition, he served on the Board of online medical records provider MediConnect Global, Inc., which was acquired in 2012 by Verisk Analytics for $350 million.

Dr. Patel is currently Chairman of USTAR's Governing Authority board and has won numerous awards including the 2006 Utah Technology Council Hall of Fame Inductee, the U.S. Small Business Administration's Business Achiever Award, Entrepreneur of the Year (Mountain West Venture Group), and most recently BioUtah's flagship award, the Willem J. Kolff Lifetime Achievement Award.

"We are grateful to Greg for his important assistance to Jade from our company's earliest days, and we are indeed honored that Dinesh is now joining our Board," said Jade CEO Arthur Klausner.  "Dinesh's wealth of experience in both drug delivery and ophthalmology represents a terrific fit for Jade as we continue to progress our locally administered, sustained-release drug products designed to treat significant ocular disorders such as corneal defects and ulcers. He is well known and respected both in the Salt Lake City area and nationally for his entrepreneurial and company-building achievements, and he has served on the Boards of numerous start-up life sciences companies."

Said Dr. Patel: "Jade represents an attractive combination of proprietary, lower-risk products addressing unmet needs in potentially blinding ophthalmic conditions. I look forward to working with the Company's Board and management team to help bring these products to the patients who need them."

About Jade Therapeutics

Jade Therapeutics, founded by Drs. Barbara Wirostko and MaryJane Rafii, is a privately held company headquartered in Salt Lake City, Utah, that develops locally administered, sustained-release formulations of (mostly) already-approved drugs for use in poorly served ophthalmic indications. This approach could enable improved therapeutic outcomes along with increased patient compliance to therapy, decreased frequency of administration and office visits, and avoidance of subsequent surgeries – ultimately resulting in better visual function with enhanced quality of life.  Jade believes that its use of proprietary administration formulations of drugs that have already received regulatory approval may significantly decrease development risks and shorten the clinical trial and regulatory approval process. Jade's lead programs focus on delivering (1) recombinant human growth hormone to help address persistent corneal epithelial defects, and (2) antibiotics to treat bacterial keratitis and corneal ulcers (utilizing funding from a recently awarded National Science Foundation SBIR grant). For additional information about Jade, please visit www.jadetherapeutics.com

Contact:
Arthur Klausner
Jade Therapeutics, Inc.
646-918-7479
Email

 

Read more news from Jade Therapeutics.

 


'/>"/>
SOURCE Jade Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... a world leader in rapid infectious disease tests, introduced the Company,s newest product, the ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited by the ... INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Biotest Pharmaceuticals Corporation (BPC), a leading manufacturer ... addition of its newest plasma collection center located at ... The 15,200 square foot state-of-the-art facility officially opened its ... the total number of BPC,s plasma collection centers to ... Chief Executive Officer said "We are pleased to become ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
Breaking Biology News(10 mins):